Compumedics Limited · ASX:CMP
Compumedics — Investor Presentation (March 2021)
24 slides from Compumedics's investor presentation, March 2021
Slide 1: Corporate presentation
Corporate presentation March 2017 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic Blood Flow Monitoring1
Slide 2: Who is Compumedics?
Who is Compumedics? A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring Diagnosing disorders including Highly sophisticated of blood flow through sleep disorders long-term epilepsy brain research the brain (Transcranial monito
Slide 3: H1 FY2021 – Performance Review
H1 FY2021 – Performance Review ▪ H1 FY21 Revenue $18.0m, EBITDA $1.9m, NPAT $1.3m H1 FY21 H1 FY20 Variance Comment The Company shipped revenues 1% lower than the prior half year, primarily due to logistical Revenue – $18.3m $18.0m -1% issues re the COVID-19 Pandemic in the reported northern hemisphe
Slide 4: H1 FY2021 – Performance Review
H1 FY2021 – Performance Review ▪ Sales orders taken were 13% higher at $20.3m for H1 FY21 compared to $18.0m for H1 FY20. Sales orders taken were 183% higher in Europe, 23% higher in Australia and 2% higher in DWL ▪ Shipped and invoiced revenues decrease 1% – largely as a result of logistical issues
Slide 5: Sales Bridge Chart – H1 FY20 to H1 FY21
Sales Bridge Chart – H1 FY20 to H1 FY21 20 18 16 14 12 10 8 6 4 2 0 Sales H1 FY20 USA Aust Asia Latin America DWL Europe Sales H1 FY21 Fall Rise 5
Slide 6: EBITDA movement – H1 FY20 to H1 FY21
EBITDA movement – H1 FY20 to H1 FY21 3 2.5 2 1.5 1 0.5 0 EBITDA H1 FY20 Sales Margin Expenses Other Revenues FX EBITDA H1 FY21 Fall Rise 6
Slide 7: H1 FY21 – Milestones achieved
H1 FY21 – Milestones achieved ▪ Core business: Profitability improves on stable sales with increasing sales orders taken, despite ongoing impacts of COVID-19 in the northern hemisphere in the 6 months to Dec 31, 2020 ▪ MEG: Compumedics/Neuroscan dual helmet Dewar MEG system, with KRISS, now planning
Slide 8: Revenue Composition at $18.0m
Revenue Composition at $18.0m 31 December 2020 By geographic region By product/market Customer Care 9% Consumables 11% Europe, USA, Sleep - 30% 29% Clinical Brain - Blood Flow Diagnostics Monitoring 23% 24% Sleep - Nexus360 Aust, 2% Brain - Asia, 14% Research Brain - Clinical 27% 14% Monitoring 18%
Slide 9: Core Business – Continuing Net Cash Position
Core Business – Continuing Net Cash Position $m FY16 H1 FY17 H1 FY18 H1 FY19 H1 FY20 H1 FY21 Cash 3.1 5.7 2.9 4.3 3.3 5.6 Trade receivables 11.9 10.9 14.8 15.5 17.3 13.3 Inventories 6.5 7.1 7.7 8.5 7.5 8.9 Prod. dev’t 2.4 2.4 3.4 5.0 9.7 3.6 Tax asset 0.5 0.5 0.7 0.0 1.5 0.9 PP&E 0.8 0.8 0.6 0.9 0.9
Slide 10: Outlook
Outlook ▪ Profitability and operating cash to improve as impact of COVID-19 Pandemic abate ▪ New products in core were delayed but now expecting to be released by end of Calendar 2021 ▪ MEG: Compumedics/Neuroscan second phase installation of Orion MEG system for Barrow Neurological Institute now bei
Slide 11: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out Sales – schematic only FY19A FY20A FY21F FY22F FY23F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – First phase installation at Barrow Neurological Institute in Phoenix, AZ, USA has
Slide 12: Core Business – Premium Focus
Core Business – Premium Focus Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics USA – 2 USA – 3 USA –
Slide 13: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range Average Product Used for Bought by selling price Hospitals, doctors Grael Sleep and neurology USD17,500 and service providers Hospitals, doctors Somte PSG Sleep USD10,000 and service providers Hospitals, doctors Siesta Sleep and neurology USD18,000 and service p
Slide 14: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Imaging Cloud based sleep Leverage existing Long term epilepsy diagnostic platforms Leverage CURRY TCD technology and Next generation market penetration for both p
Slide 15: Core Business - Growth Drivers
Core Business - Growth Drivers Compumedics/Neuroscan innovative brain analysis software (CURRY 9 close to release) and high- performance amplifiers are unrivalled world class technology. We have about 23,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Co
Slide 16: USA – CMP is number 3 Supplier
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion - Indicative More sales representatives = more revenue for both sleep and neurology Past USD3.5m FY2020 USD4.0m FY2021 USD6.0m FY2022 USD9.0m 16
Slide 17: China - We are the number 1 Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao China Sales (invoiced) – USD’s QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 12 Gansu 14 HeNan Welfang
Slide 18: Step out - Brain Imaging
Step out 1 - Brain Imaging: Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently estimated H2 FY19 – first phase of CMP has sold and software is already the gold at about 20 systems a year at an MEG installation partially installed 1 standard for the M
Slide 19: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics Nexus 360 Operational systems have been Compumedics is Key partners (professional developed for the cloud-based continuing to seek being pursued cloud sleep capture, transfer appropriate third include web, diagnostics) sold and translation of medical gr
Slide 20: Directors & Executive Team Key Management
Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 32 yrs Mr Tucson Dunn Mr. David Lawson Non Executive Director Chief Financial Officer CMP Tenure 12 months & Company Secretary CMP Tenure 20 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D. Mr. Christoph
Slide 21: Investor Summary
Investor Summary Core business continues to grow with lower cost base and addition of mid-tier International sales force Compumedics remains expansion, neurology market committed to continuing to opportunity and earnings deliver superior returns to improvement initiatives to shareholders continue to
Slide 22: Thank You
(© > COMPUMEDICS T H A N K YO U Defining Life's Signals
Slide 23: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estim
Slide 24: compumedics.com.au
CG COMPUMEDICS Vs -—__/ ly compumedics.com.au